000 05278nam a22003735i 4500
001 289391
003 MX-SnUAN
005 20160429154708.0
007 cr nn 008mamaa
008 150903s2006 xxu| o |||| 0|eng d
020 _a9781597450515
_99781597450515
024 7 _a10.1007/9781597450515
_2doi
035 _avtls000342941
039 9 _a201509030859
_bVLOAD
_c201405050249
_dVLOAD
_y201402061144
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRC681-688.2
100 1 _aMorrow, David A.
_eeditor.
_9319596
245 1 0 _aCardiovascular Biomarkers :
_bPathophysiology and Disease Management /
_cedited by David A. Morrow.
264 1 _aTotowa, NJ :
_bHumana Press,
_c2006.
300 _brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aContemporary Cardiology
500 _aSpringer eBooks
505 0 _aBiomarkers of Necrosis -- Biomarkers of Myocardial Necrosis -- Analytical Issues for Clinical Use of Cardiac Troponin -- Defining Myocardial Infarction -- Biomarkers in the Emergency Department -- Cardiac Troponin for Risk Assessment and Management of Non-ST-Elevation Acute Coronary Syndrome -- Biomarkers of Necrosis for Risk Assessment and Management of ST-Elevation Myocardial Infarction -- Cardiac Troponin After Revascularization Procedures -- Biomarkers of Necrosis in Heart Failure -- Is There a Role for Cardiac Troponin and Other Biomarkers in Patients With Pulmonary Embolism? -- Cardiac Troponin in Conditions Other Than Acute Coronary Syndromes -- Degradation of Cardiac Troponins -- Biomarkers of Ischemia -- Developing a Marker of Ischemia -- Emerging Biomarkers of Myocardial Ischemia -- Biomarkers of Inflammation -- Inflammation in Cardiovascular Disease -- Analytic Issues for Clinical Use of C-Reactive Protein -- C-Reactive Protein as a Tool for Risk Assessment in Primary Prevention -- High-Sensitivity C-Reactive Protein for Risk Assessment in Acute Coronary Syndromes -- Beyond C-Reactive Protein -- Biomarkers of Inflammation -- Biomarkers of Infection and Risk of Coronary Heart Disease -- Biomarkers of Hemodynamic Stress -- Biology of Natriuretic Peptides -- Analytic Issues for Clinical Use of B-Type Natriuretic Peptide and N-Terminal Pro B-Type Natriuretic Peptide -- Clinical Use of Natriuretic Peptides for the Diagnosis and Management of Heart Failure -- Natriuretic Peptides in Acute and Chronic Coronary Artery Disease -- Novel Markers of Hemodynamic Stress -- Biomarkers of Platelet Function and Hemostasis -- Clinical and Research Applications of Markers of Thrombosis -- Measures of Platelet Activation and Aggregation -- Monocyte-Platelet Aggregates in Patients With Ischemic Heart Disease -- Biomarkers of Dyslipidemia and Lipid Modification -- Measurement of Atherogenic Lipoproteins in Cardiovascular Risk Assessment -- Lipoprotein-Associated Phospholipase A2 and Other Lipid-Related Biomarkers in Cardiovascular Disease -- Contemporary and Future Applications of Biomarkers in clinical care -- A Multimarker Approach to Evaluation of Patients With Acute Coronary Syndrome -- Cardiac Biomarkers by Point-of-Care Testing -- Proteomics and Discovery of Cardiovascular Biomarkers -- Genetic Markers in Cardiovascular Disease.
520 _aSo rapidly has the number of cardiac assays available grown, and then improved, that current biomarkers not only diagnose cardiovascular disease, but also frame treatment strategies. In Cardiovascular Biomarkers: Pathophysiology and Disease Management, a distinguished panel of internationally recognized opinion makers and experts in clinical and laboratory medicine synthesize the latest developments in the use of cardiac biomarkers by the practicing physician. The authors focus on integrating biomarkers into the contemporary clinical management of patients with cardiovascular disease, emphasizing clinical studies, evidence-based diagnostic algorithms, and critical pathways for triage and therapy, whenever available. They also illuminate the connections between specific biomarkers and the basic pathophysiology of cardiovascular disease, explain the analytical properties of the assays relevant to clinical practice, and highlight emerging biomarkers and novel directions for biomarker development. Numerous figures, illustrations, and tables make key evidence and practical guidelines easily accessible. State-of-the-art and highly practical, Cardiovascular Biomarkers: Pathophysiology and Disease Management makes clear to today's busy cardiologists, emergency room physicians, and internists how the various assays perform, which ones they should order when evaluating their patients, and how the results of a biomarker assay can guide their therapeutic approaches.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9781588295262
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-1-59745-051-5
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c289391
_d289391